AstraZeneca announces tozorakimab demonstrated statistically significant and highly clinically meaningful reduction in COPD exacerbations in OBERON & TITANIA phase III trials: Cam ...
With a detailed data drop that AstraZeneca’s R&D chief described as an internal “science success story,” the British Big Pharma has secured an FDA priority review for what it believes could become a ...
AstraZeneca announced that full results from the positive Phase III OBERON and TITANIA trials showed that tozorakimab is the first biologic to demonstrate statistically significant and highly ...
The Biologics License Application for tozorakimab 300mg, administered once every four weeks, has been accepted for Priority Review by the US Food and Drug Administration as an add-on maintenance ...
Dati AstraZeneca a Congresso Ers e su Nejm, 'primo biologico a dimostrare un'efficacia statisticamente significativa e di ...
Bloody show adalah keluarnya lendir bercampur darah saat serviks berubah menjelang persalinan. Kenali waktu munculnya dan ...
Bayi masuk panggul umumnya terjadi pada akhir trimester ketiga. Kenali perubahan fisik, gejala lain, serta tanda yang ...
The FDA has started a priority review of AstraZeneca's IL-33-targeting antibody tozorakimab for chronic obstructive pulmonary ...
Due studi di fase III presentati al Congresso ERS 2026 e pubblicati sul New England Journal of Medicine mostrano una ...
An Evansville mother has filed a wrongful death lawsuit claiming that the Vanderburgh County Department of Child Services ...
A wrongful death lawsuit has been filed by an Evansville mother who lost her three-year-old son.
아스트라제네카(AstraZeneca, AZ)가 차세대 만성폐쇄성폐질환(COPD) 치료제로 개발 중인 '토조라키맙(tozorakimab)'이 2건의 임상 3상에서 질환 악화를 최대 34% 줄였다. 특정 염증형 환자에 국한되지 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results